Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination

Hum Vaccin Immunother. 2020 Jul 2;16(7):1595-1601. doi: 10.1080/21645515.2020.1711678. Epub 2020 Jan 24.

Abstract

Background: Short-term dynamic changes in neutralizing antibodies against EV71 and EV71-IgM after inactivated EV71 vaccine injection are unknown.

Methods: This study was designed as a randomized, open-label study and was registered at ClinicalTrials.gov (NCT03278132). In total, 120 healthy infants aged 6-35 months were randomized 1:1:1 to provide a second blood sample on day 10, day 20, or day 30 after the first vaccine dose, respectively.

Results: According to the per-protocol set, a rapid immune response against EV71 was observed 10 days after the first EV71 vaccine dose, with antibody titers ≥1:8 in 89.19% of participants (95% CI: 74.58-96.97%) on day 10, in 80.65% (95% CI: 62.53-92.55%) on day 20, in 66.67% (95% CI: 49.03-81.44%) on day 30, and in 100% (95% CI: 96.52%-.) on day 60. Based on an ELISA, the percentages of participants positive for EV71-IgM on day 0 and day 60 were 1.71% (2 out of 117) and 82.86% (87 out of 105), respectively.

Conclusions: The EV71 vaccine could be used for contingency vaccination to further control EV71-associated disease outbreaks. Caution should be taken in using the EV71-IgM test for rapid EV71 infection diagnosis after EV71 vaccine administration.

Clinical trial registration: ClinicalTrials.gov NCT03278132.

Keywords: EV71 vaccine; EV71-IgM; rapid response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Enterovirus A, Human*
  • Enterovirus Infections* / prevention & control
  • Enterovirus*
  • Humans
  • Infant
  • Vaccination
  • Vaccines, Inactivated
  • Viral Vaccines*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Vaccines, Inactivated
  • Viral Vaccines

Associated data

  • ClinicalTrials.gov/NCT03278132

Grants and funding

The study was cofunded by the Vaccine Clinical Evaluation Platform Construction Project under China National Science and Technology Major Projects [2016ZX09101120-003, 2018ZX09734004], Sinovac Biotech Co., Ltd. [PRO-EV71-4007], and Provincial Medical and Health General Research Program of Zhejiang [2017KY295].